Works matching IS 02704137 AND DT 2006 AND VI 66 AND IP 5

Results: 11

Expression of prothymosin alpha is correlated with development and progression in human prostate cancers.

Published in:

Prostate, 2006, v. 66, n. 5, p. 463, doi. 10.1002/pros.20385

By:

Shugo Suzuki;
Satoru Takahashi;
Seishiro Takahashi;
Kentaro Takeshita;
Atsuya Hikosaka;
Toshiaki Wakita;
Naoki Nishiyama;
Tamio Fujita;
Takehiko Okamura;
Tomoyuki Shirai

Publication type:

Article

Gene therapy for prostate cancer: Current strategies and new cell‐based approaches.

Published in:

Prostate, 2006, v. 66, n. 5, p. 470, doi. 10.1002/pros.20388

By:

E.J. MacRae;
A. Giannoudis;
R. Ryan;
N.J. Brown;
F.C. Hamdy;
N. Maitland;
C.E. Lewis

Publication type:

Article

Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro.

Published in:

Prostate, 2006, v. 66, n. 5, p. 557, doi. 10.1002/pros.20380

By:

Tammy E. Hedlund;
Adrie van Bokhoven;
Widya U. Johannes;
Steven K. Nordeen;
Lorraine G. Ogden

Publication type:

Article

E‐cadherin polymorphisms and haplotypes influence risk for prostate cancer.

Published in:

Prostate, 2006, v. 66, n. 5, p. 546, doi. 10.1002/pros.20374

By:

Carolina Bonilla;
Tshela Mason;
Layron Long;
Chiledum Ahaghotu;
Weidong Chen;
Aiqiu Zhao;
Aoua Coulibaly;
Frankly Bennett;
William Aiken;
Trevor Tullock;
Kathleen Coard;
Vincent Freeman;
Rick A. Kittles

Publication type:

Article

Murine androgen‐independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP.

Published in:

Prostate, 2006, v. 66, n. 5, p. 536, doi. 10.1002/pros.20369

By:

Kohsuke Uchida;
Naoya Masumori;
Atsushi Takahashi;
Naoki Itoh;
Kazunori Kato;
Robert J. Matusik;
Taiji Tsukamoto

Publication type:

Article

Superoxide dismutase in the prostate lobes of aging brown Norway rats.

Published in:

Prostate, 2006, v. 66, n. 5, p. 522, doi. 10.1002/pros.20364

By:

Angela S. Pechenino;
Terry R. Brown

Publication type:

Article

PAC1‐R null isoform expression in human prostate cancer tissue.

Published in:

Prostate, 2006, v. 66, n. 5, p. 514, doi. 10.1002/pros.20356

By:

Caterina Mammi;
Giovanni V. Frajese;
Giuseppe Vespasiani;
Stefania Mariani;
Lucio Gnessi;
Donatella Farini;
Andrea Fabbri;
Gaetano Frajese;
Costanzo Moretti

Publication type:

Article

Synthetic dimer of indole‐3‐carbinol: Second generation diet derived anti‐cancer agent in hormone sensitive prostate cancer.

Published in:

Prostate, 2006, v. 66, n. 5, p. 453, doi. 10.1002/pros.20350

By:

Venkata P.S. Garikapaty;
Badithe T. Ashok;
Kiranmayi Tadi;
Abraham Mittelman;
Raj K. Tiwari

Publication type:

Article

Prognostic value of PINP, bone alkaline phosphatase, CTX‐I, and YKL‐40 in patients with metastatic prostate carcinomaPart of the results has previously been presented at the ASCO meeting in Chicago 2003, abstract number 1525.

Published in:

Prostate, 2006, v. 66, n. 5, p. 503, doi. 10.1002/pros.20311

By:

Klaus Brasso;
Ib Jarle Christensen;
Julia S. Johansen;
Børge Teisner;
Patrick Garnero;
Paul A. Price;
Peter Iversen

Publication type:

Article

Serum hepatocyte growth factor activator inhibitor type I (HAI‐I) and type 2 (HAI‐2) in prostate cancer.

Published in:

Prostate, 2006, v. 66, n. 5, p. 447, doi. 10.1002/pros.20301

By:

Osamu Nagakawa;
Toshiya Yamagishi;
Takuya Akashi;
Kazuhiro Nagaike;
Hideki Fuse

Publication type:

Article

Enhancement of intermittent androgen ablation by “off‐cycle” maintenance with finasteride in LNCaP prostate cancer xenograft modelPresented at the Best Abstracts Plenary Session at the American Association of Cancer Research Meeting, Orlando, FL, March, 2004.

Published in:

Prostate, 2006, v. 66, n. 5, p. 495, doi. 10.1002/pros.20297

By:

Scott E. Eggener;
Jeff A. Stern;
Pankaj M. Jain;
Shane Oram;
Junkui Ai;
Xiaoyan Cai;
Kim A. Roehl;
Zhou Wang

Publication type:

Article